Syngene International Limited (SYNGENE.BO)

713,15 +3,55 (+0,50%) Alla chiusura: 03:29PM IST

Syngene International Limited

Velankani Technology Park
Block II, First Floor Electronic City Phase I
Bengaluru 560100
India
91 80 6891 9191
https://www.syngeneintl.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jonathan Brittan Hunt	MD, CEO & Executive Director	84,75M	N/D	1969
Mr. Sibaji Biswas	CFO & Executive Director	34,14M	N/D	N/D
Krishnan G	Head of Investor Relations	N/D	N/D	N/D
Ms. Priyadarshini Mahapatra C.S.	Company Secretary & Compliance Officer	4,72M	N/D	N/D
Mr. Sandeep Nair	Head of Corporate Communications	N/D	N/D	N/D
Mr. Andrew Webster	Chief Human Resources Officer	N/D	N/D	N/D
Dr. Dhananjay Patankar	Head of Pharmaceutical & Biopharmaceutical Development	N/D	N/D	N/D
Mr. Purushottam Shashikant Singnurkar	Head of Formulations Development	N/D	N/D	N/D
Mr. Ajit Manocha	Head of IT	N/D	N/D	N/D
Dr. Jayashree Aiyar Ph.D.	Head of Discovery Biology	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in INR.

Descrizione

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, Japan, Europe, the United States, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, clinical data management, regulatory, biostatistics, and medical writing services. Further, it offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Governance aziendale

L'ISS Governance QualityScore di Syngene International Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.